Skip to main content

Rheumatoid Arthritis

    EULAR 2023 Day 4 Recap
    Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.…
    Daily Recap: Day Three EULAR 2023
    RA and cancer risk in the biologic era

    RA is known to be historically associated with site specific cancers, especiall
    10 months 1 week ago
    RA and cancer risk in the biologic era RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era. https://t.co/4Pe6SIS6yb https://t.co/e2enjkXoly
    AI in RA: the story grows along the patient pathway

    The use of AI to analyse large data sets using its subset componen
    10 months 1 week ago
    AI in RA: the story grows along the patient pathway The use of AI to analyse large data sets using its subset component machine learning (ML) has taken centre stage recently in the management of rheumatic conditions including RA. https://t.co/Jv4dmV2tlU https://t.co/KkgW0cD1QM
    Should JAKs be ‘Tyk’ed off?
    RT @synovialjoints: EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 rec
    10 months 2 weeks ago
    EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
    RT @synovialjoints: The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA-
    10 months 2 weeks ago
    The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA- group. This correlated with MRI-subclinical joint score, suggesting different underlying processes Khidir S Abst#POS319 #EULAR2023 @RheumNow https://t.co/C2ADAkkSM2